IMMUNOLOGY MARKET ANALYSIS

High costs associated with immunology drugs and therapies can hamper the growth of the immunology market. Developing novel and innovative treatment options for various immunological disorders like cancer, arthritis, multiple sclerosis, and others requires massive investments in research and clinical trials. This entire process from drug discovery to final approvals is highly complex, risky and capital intensive. According to the data published by WHO in 2022, the average cost of developing a new drug and bringing it to the market is estimated to be around US$ 2.6 billion. This massive price increases the overall treatment costs significantly. For instance, on May 25, 2024, AstraZeneca suggests significant cost savings for health systems in four European countries through early CKD screening and treatment. This could prevent numerous heart attacks, heart failure hospitalizations, and strokes. Studies presented at the ERA Congress support the benefits of targeted screening and guideline-directed treatment, showing potential clinical benefits and cost savings.

Market Opportunities: Adoption of combination therapies

The adoption of combination therapies can offer growth opportunities for the market. Diseases are highly complex with multiple pathways contributing to pathogenesis. In 2021, according to a report published by World Health Organization, over 30% of cancer deaths can be linked to infectious diseases and chronic inflammation. Targeting the immune system through complementary mechanisms therefore holds promise. As research disentangles more immunological secrets, one may see tailored combination protocols that hit specific disease drivers emerging as the standards of care. This could both improve patient outcomes and sustain the growth of the immunology market well into the future by addressing currently unmet needs.